Roche Holding AG
RHO6
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
103,249
Stocks News & Analysis
stocks
10 best global blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalizations look undervalued today.
stocks
3 overvalued ASX shares going into earnings
Prices of these shares exceed our Fair Value Estimate by more than double.
stocks
The long-term case for compounders
Compounders tend to deliver steadier, more durable profit growth across full cycles, making them better suited for long-term investors.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,068.80 | 42.20 | -0.46% |
| CAC 40 | 8,191.78 | 65.25 | 0.80% |
| DAX 40 | 24,754.72 | 215.91 | 0.88% |
| Dow JONES (US) | 48,882.64 | 9.83 | -0.02% |
| FTSE 100 | 10,332.80 | 109.26 | 1.07% |
| HKSE | 26,775.57 | 611.54 | -2.23% |
| NASDAQ | 23,413.15 | 48.66 | -0.21% |
| Nikkei 225 | 52,655.18 | 667.67 | -1.25% |
| NZX 50 Index | 13,412.44 | 10.74 | -0.08% |
| S&P 500 | 6,929.80 | 9.23 | -0.13% |
| S&P/ASX 200 | 8,778.60 | 42.50 | -0.48% |
| SSE Composite Index | 4,015.75 | 102.20 | -2.48% |